Lifecore Biomedical (NASDAQ:LFCR) Third Quarter 2025 Results

Key Financial Results

• Revenue: US$35.2m (down 1.5% from 3Q 2024).
• Net loss: US$17.4m (down by 217% from US$14.8m profit in 3Q 2024).
• US$0.47 loss per share (down from US$0.48 profit in 3Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Lifecore Biomedical Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 5.8%. Earnings per share (EPS) missed analyst estimates significantly.

Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 23% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Lifecore Biomedical (at least 1 which is a bit unpleasant) , and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.